Chardan Capital and HC Wainwright Keep Arrowhead Pharmaceuticals Targets Unchanged
Chardan Capital kept its Arrowhead Pharmaceuticals price target at $115 per share, while HC Wainwright held its target at $120 per share.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Analysts at Chardan Capital reaffirmed their price target on Arrowhead Pharmaceuticals (ARWR) at $115 per share.
HC Wainwright & Co. also left its view unchanged, keeping its target for the stock at $120 per share.
why it matters
Unchanged price targets indicate that both brokerages are not revising their valuation of the stock for now. Investors often compare such decisions with the positions of other brokers, but on their own they do not amount to a forecast of where the share price will move.
tags
instruments
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗